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Compliance in black patients with non-insulin-
dependent diabetes mellitus receiving oral
hypoglycaemic therapy
H. L. VENTER, P. H. JOUBERT, G. N. FOUKARIDIS
Summary
TABLE I. REASONS FOR NON-COMPLlANCE*
Category Specific reasons for non-compliance
Disease Psychiatric illnesses
Regimen Complexity, degree of behavioural change,
duration
Poor compliance with drug therapy is an important cause of
therapeutic failure. Sixty-eight black patients with non-insu-
lin-dependent diabetes mellitus receiving oral hypoglycaemic
agents were interviewed and various factors, such as age,
sex, degree of control and type of therapy, were recorded by
means of a questionnaire. Compliance was determined by
qualitatively assessing urine for the presence of the drugs.
An alarmingly high incidence of non-compliance of 65% was
found, which could still be an under-estimation because of
the long half-life of one of the drugs involved - chlorpro-
pamide. Although interesting trends were noted, no statisti-
cally significant differences between compliant and non-com-
pliant patients were found. In the light of the high incidence
of non-compliance, a larger and more detailed study seems
to be warranted to identify problem areas and to plan appro-
priate interventions.






• After Haynes. ~
Inconvenient and inefficient clinics
Inadequate supervision, patient dissatisfaction
Inappropriate health beliefs, previous or
present non-compliance with other regimens,
family instability
Treatment compliance is often a major problem in the manage-
ment of diabetes mellitus. The extent to which serum glucose
levels can be controlled does not depend solely on the physi-
cian's skill, but also on the patients' adherence to the treatment
regimen. The fact that non-compliance is often associated with
irregular visits to clinics does not preclude other reasons for
non-eompliance. It is known that many non-eompliant patients,
although attending clinics regularly, are still fInishing the
supply of drugs of the previous month. I
Two other almost equally imponant reasons for non-eom-
pliance are unwanted side-effects and patients' forgetfulness.
Yet the other, undoubtedly imponant, general reasons for
non-compliance in pharmacotherapy, according to Haynes,2
should also be considered seriously in diabetes mellitus (Table
I). The determination of compliance is also confounded by the
fact that serum glucose determinations do not always corres-
pond with the exact date of measuring compliance and the fact
that no defInite correlation exists between fasting serum glucose
levels and compliance.3
The present study was intended to establish the extent of
poor compliance in black type II diabetic patients receiving
oral hypoglycaemic drugs, and to compare this with various
factors, e.g. age, number of drugs taken, and degree of control.
We hoped to establish the major factors associated with poor
compliance in an attempt to identify contributing factors to
see whether compliance could be improved.
Department of Pharmacology and Therapeutics, Med.ical
University of Southern Mrica and Ga-Rankuwa Hospital,
Pretoria
H. L. VENTER, M.B. CKB.
P. H. JOUBERT, M.B. B.CH., F.C.P. (S.A.), M.D.
G. N. FOUKARIDIS, M.SC., D.ED.
Accepted 12 July 1990.
Patients and methods
Sixty-eight black patients attending the Diabetic Clinic at Ga-
Rankuwa Hospital, near Pretoria, were randomly selected to
participate in the study. The patients were assessed by means
of a questionnaire, which provided information regarding age,
sex, height, body mass, drugs received (including those other
than for the treatment of diabetes mellitus), time since last
dose, and frequency of administration. The questionnaire was
completed by the medical officer serving the clinic. Additional
information regarding the last three measurements of serum
glucose concentrations and qualitative determinations of glucose
in the last three urine samples was obtained from each patient's
clinical file. Eval.uation and analysis of the last three serum
glucose concentrations and of the last three urine samples (to
determine the presence of glucose) were cartied out to assess
the degree of control. Metformin and chlorpropamide com-
pliance were assessed by quantitative determinations of these
two drugs in urine samples by means of high-pressure liquid
chromatography (HPLC).4.5 If no cWorpropamide or metforrnin
were detectable in the urine of a patient receiving the drug(s),
this was regarded as non-eompliance. The information gathered
from the questionnaire, as well as additional information, wa§
analysed statistically by the Institute of Biostatistics of the
South African Medical Research Council using univariate
. analysis, descriptive statistics and the Mann-Whimey U-test.
Results
Sixty-eight patients were interviewed; their mean (± SD) age
was 55,6 ± 11,5 years. There were 26 men and 42 women in
the study; the average duration of diabetes mellitus was 5,2
years, and 73% of the patients were obese. Among this group
of patients receiving oral hypoglycaemic therapy chlorpro-
pamide was used by 57 patients and metformin by 53. A total
of 42 patients received both drugs, whereas 15 received chlor-
propamide only and 11 metforrnin only.
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Compliant v. non-compliant patients
We were unable to detect one or more of the drugs taken in
the urine of 44 (65%) of the 68 patients interviewed. These 44
patients are compared with the rest of the patients in Table 11.
72,7% of patients, who also'received cWorpropamide, were
compliant for cWorpropamide. The mean (± SD) serum glu-
cose level was 9,24 ± 4,0 I mmoVI and the average duration of
diabetes was 5,55 ± 4,36 years.
* Average values of last 3 serum glucose values. None of these differences
were statistically significant
Discussion
The authors are indebted to Dr C. van der Merwe for' the
statistical analysis, Dr L. van Heerden, Medical Superintendent,
Ga-Rankuwa Hospital, for permission to publish, and to Mrs M.
Fourie and Mrs C. Jansen van Rensburg for typing the manuscript.
This work was sponsored by a grant from the South African
Medical Research Council.
This pilot study had many limitations, e.g. the fact that the 68
patients were assessed once only, and that the only contact
with the patient consisted of a single interview (with the only
aim being to gather information for completing a question-
naire). The method employed in this study differs to a signifi-
cant extent from the more elegant design of the study con-
ducted by Buchanan er al. I .
It must be remembered that there is no infallible method
for the measurement of compliance. Even direct measurements,
e.g urinary excretion of drugs, have certain limitations. One
should consider the fact that chlorpropamide is excreted very
slowly in the urine; the elimination half-life of chlorpropamide
is 35 hours. 6•7 After therapy for 16 days, 20 additional days
may be required for clearance of the drug from the blood;
therefore many patients, appearing to be compliant, might
actually be non-compliant (i.e. taking drugs irregularly). A
non-compliance figure of 65% (the present study) is therefore
still very conservative and might well be much higher.
Despite the shortcomings, some interesting observations
were made. It was found that compliance had no influence on
mean serum glucose levels; for example no differences in mean
serum glucose levels between compliant and non-compliant
patients receiving chlorpropamide only were found. This is in
accordance with the findings of Eshelman. 3 Although the
mean serum glucose levels of patients receiving metformin
were marginally lower for the non-compliant than for the
compliant patients, the standard deviation was greater (3,11 v.
2,35) in the non-compliant group; this indicates a wider
distribution of individual serum glucose levels among the
patients who were non-compliant for metformin.
Gordis7 stated that there is no correlation between com-
pliance and age, sex, educational status, occupation, income or
population group. We found some differences in compliance
regarding age, sex, duration of illness, drug dosages, time since
last dose and serum glucose levels (Table II), but these
differences were not statistically significant. This calls for
more elaborate studies, which should include more' patients.
The only statistically significant difference in the present
study, viz. a difference in mean body mass, was found between
cWorproparnide-compliant !lI1d cWorpropamide-non-compliant
groups; a likely explanation for this fmding is the fact that
chlorpropamide is known to stimulate the appetite and to
cause an increase in body mass, probably because it (as well as
the other sulphonylureas) causes degranulation of the f3-cells
in the eI1docrine pancreas, increasing the rate of secretion of
insulin, and also an increase in the number of insulin receptors.8
This study should be seen as exploratory, and the ,results,
although interesting, should be seen in this light. 'Since the
incidence of non-compliance is high, further more elaborate
and methodologically more refmed studies addressing this
problem in black patients with type 11 diabetes mellitus
receiving oral hypoglycaemic drugs are indicated.





6,5 ± 5,5 4,5 ±3,1
314,7 ± 189,4 379,7 ± 205,3
1470,6 ± 528,6 1381,3 ± 561,6
5,4 ±4,5 9,3 ± 8,9
TABLE 11. COMPARATIVE CHARACTERISTICS OF













Time since last dose (h)
Serum glucose values
(mgll)*
Patients receiving chlorpropamide only
(N = 15)
Subjects meeting this criterion were non-compliant in 50%
of cases according to negative urine sample determinations for
chlorpropamide. The mean (± SD) serum glucose level for
these patients was 9,68 ± 5,1 mmoVl. The concordant values
for the compliant and non-compliant patients were 9,1 ± 5,36
mmoVI and 10,39 ± 5,76 'mmoVI, respectively (P = 0,05).
Fifty-eight per cent of the non-compliant group were women,
and the average duration of the illness was 2 years less than
that of the compliant group. A significant increase in body
mass was found in the compliant patients compared with
non-compliant patients (73,7 ± 10,4 kg v. 66,1 ± 8,6 kg
(P = 0,0313)).
Patients receiving metformin only (N = 11)
In this group 36% of patients were non-compliant. The
mean (± SD) serum glucose level was 6,96 ± 2,60 mmoVl. A
slightly lower value for non-compliant than for compliant
patients (6,8 ± 3,1 mmoVI v. 6,94 ± 2,35 mmoVl) was found
(P = 0,05). Ninety-two per cent of the non-compliant patients
were women, and the average duration of the illness was 2,3
years less than that of the compliant group. Although statis-
tically insignificant, there was a trend for the mean body mass
to be lower among compliant patients (81,04 ± 6,04 kg v.
84,85 ± 9,4 kg).
Patients recelvmg both chlorpropamide and
metformin (N = 42)
The patients receiving both cWorpropamide and metformin
were non-compliant in 78% of cases. They were compliant for
chlorpropamide in 45,2% of cases and for metformin in 66,7%
of cases. Eighty-six per cent in the non-compliant group for
chlorpropamide, also receiving metformin, were compliant for
metformin. Among the non-compliant group for metformin
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